ALLYX THERAPEUTICS INC
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $23.0Mattributed |
|---|---|
| Latest round | grant, $3.3M, 2024-01-01attributed |
| Founded | 2019 |
| Headquarters | NEW HAVEN, Connecticut |
| Industry | bio |
| Stage | unknown |
| Website | allyxthera.com |
Allyx Therapeutics develops ALX-001, a candidate designed to preserve synapses in Alzheimer's and Parkinson's disease. It targets patients suffering progressive neurodegenerative disease. Differentiator: synaptic protection rather than the typical amyloid- or tau-targeting disease modification.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-01-01 | grant | $3.3M | undisclosed |
Detected tech stack
Nginx, The SEO Framework, reCAPTCHA, Google Analytics, Google Tag Manager, FitVids.JS 4.24.3, jQuery Migrate 3.4.1, Divi, DoubleClick Floodlight, WordPress, PHP, MySQL
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $3.3M | attributed | sbir named as publisher. No document URL on file. |
| Total raised $23.0M | attributed | sbir named as publisher. No document URL on file. |
| Company existence | self-reported | allyxthera.com, read 2026-05-02 |
| Description | self-reported | allyxthera.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.